

## References

1. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. *Neurology*. 2002;59:499-505.
2. de Seze J, Stojkovic T, Breteau G, et al. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. *Brain*. 2001;124:1509-1521.
3. Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. *Mult Scler*. 2005;11:373-377.
4. Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. *Nat Clin Pract Rheumatol*. 2008;4:381-386.
5. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. *Nat Immunol*. 2007;8:913-919.
6. Murray TJ. *Multiple Sclerosis: The History of a Disease*. New York, NY: Demos Medical Publishing, LLC; 2005.
7. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008;372:1502-1517.
8. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. *Clin Neurol Neurosurg*. 2006;108:327-332.
9. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. *Brain Res Brain Res Rev*. 2005;48:185-195.
10. Li J, Baud O, Vartanian T, et al. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. *Proc Natl Acad Sci U S A*. 2005;102:9936-9941.
11. Howe CL, Mayoral S, Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. *Neurobiol Dis*. 2006;23:731-739.
12. John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. *Nat Med*. 2002;8:1115-1121.
13. Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. *FASEB J*. 2006;20:1209-1211.
14. Compston A. The pathogenesis and basis for treatment in multiple sclerosis. *Clin Neurol Neurosurg*. 2004;106:246-248.

15. Waxman SG. Demyelinating diseases—new pathological insights, new therapeutic targets. *N Engl J Med*. 1998;338:323-325.
16. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. *Ophthalmology*. 2006;113:324-332.
17. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. *Ann Neurol*. 2005;58:840-846.
18. Simon JH. Update on multiple sclerosis. *Radiol Clin North Am*. 2006;44:79-100.
19. Minagar A, Toledo EG, Alexander JS, Kelley RE. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. *J Neuroimaging*. 2004;14(3 suppl):5S-10S.
20. Toledo J, Sepulcre J, Salinas-Alaman A, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. *Mult Scler*. 2008;14:906-912.
21. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. *Neurology*. 2007;69:1603-1609.
22. Sergott RC, Frohman E, Glanzman R, Al-Sabbagh A; OCT in MS Expert Panel. The role of optical coherence tomography in multiple sclerosis: expert panel consensus. *J Neurol Sci*. 2007;263:3-14.
23. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. *Neurologist*. 2007;13:2-11.